2023-509961-19-00CompletedPhase 1
Investigation of pharmacokinetics, safety and tolerability of a single subcutaneous dose of NNC0487-0111 in participants with various degrees of renal impairment and normal renal function.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 12 Jun 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 42 (actual)
- First submitted
- 26 Mar 2024
- Start date
- 18 Jul 2024
- Lead sponsor
- Novo Nordisk A/S
- Diseases
- Obesity
- EU CT number
- 2023-509961-19-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 42
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Charite Research Organisation GmbH | Berlin | Germany | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.